The mRNA Vaccines and Therapeutics Market is expected to register a CAGR of 18.2% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Type (mRNA Vaccines and mRNA Therapeutics). The market is further segmented based on by Application (Infectious Diseases, Cancer Immunotherapy, Genetic Disorders, Rare Diseases). The report is segmented based on End-User (Hospitals & Clinics, Research Institutes, Biopharmaceutical Companies). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report mRNA Vaccines and Therapeutics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
mRNA Vaccines and Therapeutics Market Segmentation
Type- mRNA Vaccines and mRNA Therapeutics
- Infectious Diseases
- Cancer Immunotherapy
- Genetic Disorders
- Rare Diseases
- Hospitals & Clinics
- Research Institutes
- Biopharmaceutical Companies
Strategic Insights
mRNA Vaccines and Therapeutics Market Growth Drivers- Increasing Demand for mRNA Vaccines: The COVID-19 pandemic showcased the efficacy of mRNA vaccines, boosting global interest in their potential for other infectious diseases. Their rapid development, effectiveness, and scalability compared to traditional vaccine methods have led to sustained demand for mRNA technologies, propelling the market forward in both vaccines and therapeutics.
- Advances in mRNA Technology: Ongoing technological improvements have made mRNA vaccines and therapeutics more efficient, cost-effective, and easier to manufacture. This has encouraged investments from pharmaceutical companies, expanding the applications of mRNA beyond vaccines to cancer, autoimmune diseases, and genetic disorders. Continued R&D in mRNA platforms promises to further increase their adoption.
- Favorable Regulatory Environment: Governments and health organizations are increasingly supportive of mRNA vaccine and therapeutic research. The accelerated approval pathways adopted during the COVID-19 pandemic for mRNA vaccines have paved the way for quicker market access. The regulatory focus on innovation, combined with incentives for biotech advancements, will drive continued growth in the mRNA sector.
- Personalized mRNA Vaccines: Personalized mRNA vaccine development is gaining momentum as researchers explore tailoring vaccines to individual genetic profiles. This trend has the potential to improve vaccine effectiveness by targeting specific immune responses, enhancing the treatment of diseases like cancer and rare genetic disorders. The growing interest in precision medicine is likely to drive innovation in this area.
- mRNA in Cancer Treatment: Beyond vaccines, mRNA technology is being increasingly explored for cancer therapies. By instructing cells to produce cancer-specific proteins, mRNA treatments can stimulate the immune system to target and eliminate cancer cells. Ongoing clinical trials and partnerships between pharmaceutical companies highlight the growing investment and enthusiasm for mRNA as a promising cancer treatment option.
- Collaborations and Partnerships: The mRNA vaccine and therapeutic market is seeing an increase in partnerships between biotech companies, pharmaceutical giants, and academic institutions. These collaborations aim to leverage expertise and resources to accelerate the development of novel mRNA-based therapies. As the market expands, such partnerships will be critical in overcoming challenges and ensuring rapid advancement.
- Emerging Infectious Diseases: mRNA technology offers an opportunity to rapidly respond to emerging infectious diseases. The ability to develop mRNA vaccines within weeks of identifying new pathogens creates a significant market opportunity. Companies investing in this technology can position themselves as leaders in global health responses, providing critical solutions for pandemics and regional outbreaks.
- Rare Disease Therapies: mRNA-based therapeutics hold immense potential for treating rare genetic diseases. By directly addressing the genetic mutations causing these disorders, mRNA offers a targeted approach that could replace current methods that are less effective. This opportunity opens up new markets for companies to cater to underserved patient populations with previously limited treatment options.
- Global Vaccination Programs: As governments invest in long-term vaccination programs, there is a growing opportunity for mRNA vaccine developers to play a central role in public health initiatives. The scalability of mRNA platforms allows for cost-effective vaccine production in large quantities, making it possible to expand vaccination efforts globally, especially in developing regions.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the mRNA Vaccines and Therapeutics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the mRNA Vaccines and Therapeutics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Approximately 150-200 word file pages is the standard report
Key drivers include the success of COVID-19 vaccines, technological advancements in mRNA platforms, the need for rapid vaccine development, and the potential to address rare and genetic diseases
Challenges include high production costs, storage requirements (cold chain logistics), limited infrastructure in developing regions, and regulatory hurdles in different regions.
Growth opportunities include expanding mRNA applications in cancer immunotherapy, rare genetic disorders, and personalized medicine, which are areas with increasing patient demand.
Leading companies include Moderna, Pfizer, BioNTech, CureVac, and Arcturus Therapeutics, with significant contributions from pharmaceutical giants and specialized biotech firms
Risks include the possibility of regulatory delays, safety concerns related to long-term effects, challenges in scaling production, and market competition from traditional vaccine and therapeutic methods.
- Boehringer Ingelheim International GmbH
- Cambrex Corporation
- CordenPharma International
- Moderna, Inc.
- Pfizer, Inc.
- BioNTech SE
- CureVac AG
- Translate Bio
- Arcturus Therapeutics
- GSK plc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For